Plasminogen activation system (PAS)

The Plasminogen activation system (PAS) is a sophisticated proteolytic cascade essential for maintaining vascular patency through the degradation of fibrin clots, a process known as fibrinolysis (StatPearls). It comprises the zymogen plasminogen, its primary activators—tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)—and their respective inhibitors, such as plasminogen activator inhibitor-1 (PAI-1) and alpha-2-antiplasmin (UniProt). Beyond its role in hemodynamics, the PAS is a critical mediator of extracellular matrix remodeling and cell migration, which are pivotal in physiological processes like wound healing and pathological states like cancer metastasis (NCBI). In clinical practice, the system is targeted by thrombolytic agents to treat acute ischemic stroke and myocardial infarction by accelerating clot dissolution (PubMed). Conversely, antifibrinolytic agents like tranexamic acid are used to stabilize clots and reduce bleeding in surgery or trauma by inhibiting plasmin activity (NIH). The balance of this system is vital, as dysregulation is linked to both thrombotic disorders and invasive tumor growth (PubChem).

Other names

Fibrinolytic systemPlasminogen-plasmin systemuPA/uPAR system

Drugs targeting the Plasminogen activation system primarily function by either activating the conversion of plasminogen to plasmin to promote fibrinolysis (e.g., tPA analogs) or by inhibiting plasmin activity and its binding to fibrin to prevent clot dissolution (e.g., tranexamic acid). Some agents act as direct serine protease inhibitors or competitive inhibitors of the lysine-binding sites on plasminogen (StatPearls, NIH).